Tuesday, October 17, 2017 2:19:16 AM
The "other" M/B is not mentioned
It is : https://stocktwits.com
The poster is : /thebengalikid
A poster since 24 April 17
741 posts(?)
Cel-Sci IR is not STUPID enough to give INSIDER information to ONE person. It is illegal.
If one asks IR a question there is a good chance that there will be no response. If there is a response there is LEGAL statement warning the recipient that they are NOT to post that information.
That person has possibly received INSIDER information that may have trading value that is not public knowledge .
Suppose , the bengali kid did not receive any IR information?
Read some of the guys recent posts. what you'll see is OLD information from as far back as P2.That OLD information is treated as if it's new.
1 )"they are looking to increase survival by 10% from what already exists. Being at 50% 3 yr means 25% overall increase" Oct. 16 at 6:02 PM thebengalikid
2 )"yes 10% overall survival is the goal, MK doing much better at 50% 3 year survival,*** study ends when certain statistics have reached *** Oct. 16 at 5:12 PM thebengalikid
3 )"spoke with IR, attorneys feel arbitration will be over before the end of this year and ***MK P3 survival is at 50% so far***Oct. 16 at 4:39 PM thebengalikid
yankeenyc27... NOTE : "survival is at 50% " = 50% have passed away. How many patients have been treated? How many have to pass away , before the FDA can evaluate S.O.C. VS. M.K.?
" ***study ends when certain statistics have reached"***... 298 deaths is when the FDA can "see" if there is a statistical difference.
ASSUME ,880 have been treated, 50% deceased = FAR MORE THAN 298!
thebengalikid .......
@cloroxpower @calem Oct. 16 atthebengalikid 6:31 PM
thebengalikiday @BioGod read this up too
seekingalpha.com/article/20...
yankeesnyc27 NOTE: The seeking Alpha reference is about 42 months old and is one of two posts of " The Frugal Norwegian".
SOOOO.... Did someone quote from IR????
IMO ; NO !
I ask that others ( including me ) contact IR AND also file an SEC complaint.
Recent CVM News
- CEL-SCI Appoints Mario Gobbo to Its Board of Directors • Business Wire • 04/23/2024 01:00:00 PM
- CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology • Business Wire • 03/19/2024 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/07/2024 04:33:42 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/07/2024 04:33:13 PM
- CEL-SCI Corporation Issues Letter to Shareholders • Business Wire • 03/06/2024 01:45:00 PM
- CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results • Business Wire • 02/15/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:31:12 PM
- CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock • Business Wire • 02/13/2024 05:00:00 PM
- CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock • Business Wire • 02/09/2024 01:30:00 PM
- CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug • Business Wire • 02/06/2024 02:00:00 PM
- European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine® • Business Wire • 01/31/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 02:06:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 02:03:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 02:00:11 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 12/22/2023 09:01:06 PM
- CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments • Business Wire • 12/22/2023 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 12/21/2023 09:15:39 PM
- UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer • Business Wire • 12/04/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 10:25:18 PM
- CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock • Business Wire • 11/20/2023 09:15:00 PM
- CEL-SCI Announces Pricing of $5 Million Offering of Common Stock • Business Wire • 11/16/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 09:01:26 PM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM